| Jenken's technology platform is a portfolio of small molecule, orally delivered TLR4 antagonists which modulate excessive inflammatory responses that lead to chronic inflammation and its complications. Published literature clearly points to the inhibition of the TLR4 signaling pathway by such antagonists as effective therapy in the treatment and prevention of several diseases including: chronic liver diseases associated with viral (HCV/HBV) infections and non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD/Crohn’s), multiple sclerosis and rheumatoid arthritis. |
Technology Overview Disease Programs Products |